[1]苗玉迪a,魏绪仓b.达沙替尼联合氟达拉滨对慢粒K562细胞的抑制作用研究[J].现代检验医学杂志,2015,30(05):70-72.[doi:10.3969/j.issn.1671-7414.2015.05.021]
　MIAO Yu-dia,WEI Xu-cangb.Study on Inhibition of Dasatinib and Fludarabine to CML K562 Cells[J].Journal of Modern Laboratory Medicine,2015,30(05):70-72.[doi:10.3969/j.issn.1671-7414.2015.05.021]
点击复制

达沙替尼联合氟达拉滨对慢粒K562细胞的抑制作用研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年05期
页码:
70-72
栏目:
论著
出版日期:
2015-12-10

文章信息/Info

Title:
Study on Inhibition of Dasatinib and Fludarabine to CML K562 Cells
作者:
苗玉迪a; 魏绪仓b
陕西省人民医院a.血液内科；b.血液病研究室，西安710068
Author(s):
MIAO Yu-dia; WEI Xu-cangb
a.the Blood Internal Medicine； b.Department of Blood Disease，Shaanxi Province People’s Hospital，Xi’an 710068，China
关键词:
达沙替尼; 氟达拉滨; 白血病; 慢粒K562细胞; 抑制作用
分类号:
R557.3；R446.113
DOI:
10.3969/j.issn.1671-7414.2015.05.021
文献标志码:
A
摘要:
目的探讨达沙替尼联合氟达拉滨对慢粒K562细胞的抑制作用。方法选取慢粒K562细胞株进行研究，采用MTT法分别测定单独使用达沙替尼和氟达拉滨对慢粒K562细胞的抑制率，以及达沙替尼联合氟达拉滨对诱导K562细胞的抑制率。根据金氏方程计算2种药物联合的抑制率及凋亡情况的协同作用及治疗效果。金氏公式为：q=D1+2/(D1+D2-D1×D2)，q表示2种药物联合作用的抑制率，D1和D2是单独用药作用的抑制率。当q值＞1.15表示为协同作用。经过不同浓度的达沙替尼(1，5，10 μg/L)和氟达拉滨(1，2.5，5 ng/L)单独处理后或联合处理(1 μg/L达沙替尼+1 ng/L氟达拉滨)，(5 μg/L达沙替尼+2.5 ng/L氟达拉滨)，(10 μg/L达沙替尼+5 ng/L氟达拉滨)24 h后，K562细胞的增殖受到明显的抑制，且达沙替尼和氟达拉滨具有协同效应。结果在相同的时间范围内，氟达拉滨和达沙替尼对K562细胞的抑制作用呈剂量依赖性，由于5 μg/L达沙替尼和2.5 ng/L氟达拉滨均能明显抑制K562细胞的增殖作用，因此在后续的实验过程中，选择该浓度作为细胞处理的终浓度。实验组和对照组的抑制率，差异均有统计学意义(t＝39.998，P<0.05)。达沙替尼联合氟达拉滨存在协同抑制慢粒K562细胞的作用(q＞1.15，P＜0.05)；低浓度(1 μg/L)达沙替尼对慢粒K562细胞p-BCR/ABL水平的下调作用(31.8％±1.9％)明显优于高浓度(10 ng/L)氟达拉滨(15.2％±2.1％)，联合药物更明显下调慢粒K562细胞p-BCR/ABL水平的表达(49.8％±1.1％)，差异具有统计学意义(t＝6.754，P＜0.05)。达沙替尼联合氟达拉滨能改善白血病，提高凋亡细胞的数量。结论达沙替尼联合氟达拉滨作用于白血病慢粒K562细胞具有协同抑制作用，加速慢粒K562细胞的凋亡，具有重要的临床意义。
Abstract:
ObjectiveTo study the inhibition of Dasatinib and fludarabine on CML K562 cells．MethodsCML K562 cells were analyzed，the MTT method was used to determine the inhibition of CML K562 cells，dasatinib and fludarabine,respectively,and the inhibition rate of dasatinib joint fludarabine to CML K562 cells．According to kimformula,calculated the synergistic effect and the therapeutic effect of the inhibition rate and apoptosis of 2 kinds of drug combinations ［Kim formulais：q=D1+2/(D1+D2-D1×D2)］．q means the inhibition rate of two drug combination，D1 and D2 inhibition rate of the medicine effect．When the q value is greater than 1.15 was expressed as synergy，according to the guinness book of equation proved the inhibition rate and apoptosis of synergy and the treatment effect of two drug combination．Determined by MTT method to detect the results showed that after different concentrations for Dasatinib (1，5，10 μg/L) and fluorine (1，2.5，5 ng/L) after treatment alone or combined processing (1 μg/L Dasatinib＋1 ng/L fludarabine)，(5 μg/L Dasatinib+2.5 ng/L fludarabine)，(10 μg/L Dasatinib+5 ng/L fludarabine) after 24 h，inhibition of the proliferation of K562 cells were obvious，and Dasatinib and fluorine had a synergistic effect．ResultsAt the same time within the scope of fluorine dara marina and for sand for inhibition of K562 cells was dose dependent，because mu 5 g/L for sand for shore and 2.5 ng/L fluorine dara could significantly inhibits the proliferation of K562 cells，so in subsequent experiments，chose the concentration as the final concentration cell processing．The inhibition rate of the experimental group and control group，all had statistical significance (t=39.998，P< 0.05)．For sand for joint fluorine dara marina exist K562 cells of synergistic inhibition CML (q>1.15，P<0.05)；Low concentrationmu (1 g/L) for sand for K562 cells of CML p-lower BCR/ABL level role (31.8%±1.9%) high concentration (10 ng/L) was obviously better than the fluorine dara marina (15.2%±2.1%)，combination of drugs more apparent K562 cells by CML p-the expression of BCR/ABL levels (49.8%±1.1%)，statistically significant difference (t=6.754，P<0.05)．For sand for joint fluorine dara marina can improve leukemia，increase the number of apoptotic cells．ConclusionDasatinib and fludarabine effect on CML K562 cellshave synergistic inhibition effect，accelerate the apoptosis of CML K562 cells，has important clinical significance．

参考文献/References:

［1］苗玉迪，焦红侠，王晖，等．氟达拉滨联合格列卫诱导k562细胞耐药性的研究［J］．现代检验医学杂志，2012，27(5)：11-14． Miao YD，Jiao HX，Wang H，et al．Impact of K562 cells，resistance induced by the Fludarabine joint STI571［J］．J Mod Lab Med，2012，27(5)：11-14．
[2]肖若芝，何程明，王立琳，等．索拉非尼联合柔红霉素对白血病K562细胞的抑制作用［J］．中国病理生理杂志，2013，26(7)：1356-1361． Xiao RZ，He CM，Wang LL，et al．Combination of sorafenib and daumorubicin has antileukemic activity on K562 cells［J］．Chinese Journal of Pathophsiology，2013，26(7)：1356-1361．
[3]谢杏仪，黎毓光，韩泽平，等．Hsa-miR-203联合伊马替尼对慢性粒细胞白血病K562细胞的作用［J］．安徽医药，2013，17(10)：1764-1766． Xie XY，Li YG，Han ZP，et al．Effect of imatinib combined with Hsa-miR-203 gene on chronic myeloid leukemia cells line K562［J］．Anhui Medical and Pharmaceutical Journal，2013，17(10)：1764-1766．
[4]王玮，孙秉中，谢红，等．伊马替尼联合P27基因克隆对慢性粒细胞白血病K562细胞的作用［J］．实用医学杂志，2013，22(13)：1473-1476． Wang W，Sun BZ，Xie H，et al．Effect of imatinib combined with P27 gene clone on chronic myeloid leukemia cells line K562［J］．Journal of Practical Medicine，2013，22(13)：1473-1476．
[5]杜圣红，何丛，贾培敏，等．伊马替尼联合槲皮素对K562细胞增殖、凋亡的影响及其机制研究［J］．诊断学理论与实践，2013，12(6)：610-614． Du SH，He C，Jia PM，et al．Effect of combined use of imatinib and quercetin on proliferation and apoptosis of K562 cell line［J］．J Diagn Concepts Pract，2013，12(6)：610-614．
[6]陈琰，肖若芝，王立琳，等．U0126增强索拉非尼对K562细胞增殖抑制、凋亡及诱导分化作用［J］．中国病理生理杂志，2011，27(5)：859-864． Chen Y，Xiao RZ，Wang LL，et al．U0126 enhance soraferib-induced proliferation inhibition，apoptosis and differentiation in K562 cell［J］．Chinese Journal of Pathophysiology，2011，27(5)：859-864．
[7]王彦，冯文莉．伊马替尼治疗慢性粒细胞白血病的耐药机制与对策［J］．生命的化学，2013，33(4)：407-412． Wang Y，Feng WL．Mechanism and strategy against Imatinib-resistant chronic myeloid leukemia［J］．Chemistry of Life，2013，33(4)：407-412．
[8]肖若芝，王立琳，阮星星，等．索拉非尼联合柔红霉素对K562细胞株协同作用的研究［J］．中国实验血液学杂志，2010，18(3)：621-624． Xiao RZ，Wang LL，Ruan XX，et al．Effect of sorafenib combined with daunorubicin on K562 cell line［J］．Journal of Experimental Hematology，2010，18(3)：621-624．
[9]黄之虎，韦思羽，农朝赞，等．三氧化二砷联合miR-203对人白血病K562细胞的抑制作用及其机制［J］．中国肿瘤生物治疗杂志，2014，21(5)：499-454． Huang ZH，Wei SY，Nong CZ，et al．Inhibiting effects of arsenic trioxide in combination with miR-203 on leukemic K562 cells and its mechanisms［J］．Chin J Cancer Biother，2014，21(5)：499-454．
[10]孙晶，赵艳红，周晋．达沙替尼治疗核心结合因子相关性急性髓系白血病的理论基础及最新临床研究［J］．中国新药杂志，

相似文献/References:

[1]王 磊,周枫叶,姜春菲,等.HPLC-MS/MS法测定白血病患者血浆伊马替尼与达沙替尼浓度[J].现代检验医学杂志,2016,31(01):128.[doi:10.3969/j.issn.1671-7414.2016.01.037]
　WANG Lei,ZHOU Feng-ye,JIANG Chun-fei,et al.Determination of Imatinib and Dasatinib in Leukemia Patients Plasma by HPLC-MS/MS[J].Journal of Modern Laboratory Medicine,2016,31(05):128.[doi:10.3969/j.issn.1671-7414.2016.01.037]

备注/Memo

备注/Memo:
作者简介：苗玉迪(1975-)，女，硕士在读，主治医师。
更新日期/Last Update: 1900-01-01